These may include nausea, decreased appetite, vomiting, constipation, diarrhea, bloating, or abdominal discomfort
Diabetologia 64 , 26092652 (2021)
Licensed pharmacotherapy , such as orlistat (available on NHS prescription) or, more recently, semaglutide (Wegovy), which has received NICE approval for specific indications (NICE TA875), and tirzepatide (Mounjaro), which has received NICE approval for weight management (2024 NICE technology appraisal)
What really sets our approach apart is the personalization
Clinical studies of CagriSema have measured endpoints such as body weight change, glycemic measures, and cardiometabolic risk markers in adults with overweight/obesity (including some with type 2 diabetes)
Dissolving microneedles for transdermal drug delivery